

Special Issue

Advances in Malignant Pleural Mesothelioma (MPM)

Message from the Guest Editors

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer associated with asbestos exposure, and its incidence is increasing globally. The complex biology of MPM is poorly understood, and the largest genomic studies to date have demonstrated that mesothelioma is primarily defined by loss-of-function alterations in tumor-suppressor genes. This Special Issue will describe new developments in the field of biology with genomics and highlight the most relevant data from clinical trials regarding recent treatment strategies for MPM, with a particular focus on immunotherapeutic and targeted approaches. For this Special Issue of *Cancers*, we invite you to submit original research or a comprehensive review of the state of art of MPM research, including, but not limited to:

- Histological and molecular characteristics;
- Radiology and tumor response;
- Surgery;
- Molecular alterations;
- The tumor microenvironment;
- Targeted agents;
- Cellular therapies;
- Predictors of response to immunotherapy;
- Further trials of interest and future perspectives.

We look forward to receiving your contributions.

Guest Editors

Dr. Susana Cedrés

Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain

Dr. Santiago Ponce-Aix

Gustave Roussy Cancer Campus Grand Paris, Paris, France

Deadline for manuscript submissions

closed (10 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/149595

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)